Patents by Inventor Joseph E. Pero

Joseph E. Pero has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200261411
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Application
    Filed: February 21, 2020
    Publication date: August 20, 2020
    Inventors: Edward J. BRNARDIC, Carl A. BROOKS, Brian Griffin LAWHORN, Guosen YE, Linda S. BARTON, Brian W. BUDZIK, Jay M. MATTHEWS, John Jeffrey McATEE, Jaclyn R. PATTERSON, Joseph E. PERO, Robert SANCHEZ, Matthew Robert SENDER, Lamont Roscoe TERRELL, David J. BEHM, James V. THOMAS
  • Patent number: 10590077
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: March 17, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Edward J. Brnardic, Carl A. Brooks, Brian W. Budzik, Brian Griffin Lawhorn, Jay M. Matthews, John Jeffrey McAtee, Joseph E. Pero, David J. Behm
  • Patent number: 10588891
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: March 17, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Edward J. Brnardic, Carl A. Brooks, Brian Griffin Lawhorn, Guosen Ye, Linda S. Barton, Brian W. Budzik, Jay M. Matthews, John Jeffrey McAtee, Jaclyn R. Patterson, Joseph E. Pero, Robert Sanchez, Matthew Robert Sender, Lamont Roscoe Terrell, David J. Behm, James V. Thomas
  • Publication number: 20200071310
    Abstract: The present invention relates to N-aryl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Application
    Filed: December 11, 2017
    Publication date: March 5, 2020
    Inventors: Brian W. BUDZIK, Peng LI, Joseph E. PERO, Charlotte Mary GRIFFITHS-JONES, Thomas Daniel HEIGHTMAN, David NORTON, Hendrika Maria Gerarda WILLEMS, Alison Jo-Anne WOOLFORD
  • Publication number: 20200055863
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Application
    Filed: July 29, 2019
    Publication date: February 20, 2020
    Inventors: Zehong WAN, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E. Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
  • Publication number: 20200031820
    Abstract: The present invention relates to 3-carboxylic acid pyrrole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Application
    Filed: December 11, 2017
    Publication date: January 30, 2020
    Inventors: Brian W. BUDZIK, Peng LI, Joseph E. PERO, Charl mARY GRIFFITHS-JONES, Thomas Daniel HEIGHTMAN, Dvid NORTON, Hendrika Maria WILLEMS, Alison Jo-Anne WOOLFORD
  • Patent number: 10442778
    Abstract: Disclosed are compounds of Formula A-1, or a salt thereof: Formula A-1, where J, K, Q and R1 are as defined herein, which compounds have properties for inhibiting sodium ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A-1 or their salts, and methods of treating pain (e.g. chronic pain), or cough or itch disorders using the same.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: October 15, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Anthony J. Roecker, Mark E. Layton, Thomas J. Greshock, Joseph E. Pero, Michael J. Kelly, III, Ting Zhang
  • Patent number: 10428078
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: October 1, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
  • Patent number: 10364256
    Abstract: The present invention relates to biaryl pyrazole compounds of Formula (I) methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: July 30, 2019
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, Astex Therapeutics Limited
    Inventors: James Callahan, Jeffrey K. Kerns, Peng Li, Tindy Li, Brent W. McCleland, Hong Nie, Joseph E. Pero, Thomas Glanmor Davies, Maria Grazia Carr, Charlotte Mary Griffiths-Jones, Thomas Daniel Heightman, David Norton, Marinus Leendert Verdonk, Alison Jo-Anne Woolford, Hendrika Maria Gerarda Willems
  • Publication number: 20190216774
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Application
    Filed: September 20, 2017
    Publication date: July 18, 2019
    Inventors: Edward J. BRNARDIC, Carl A. BROOKS, Brian Griffin LAWHORN, Guosen YE, Lisa S. BARTON, Brian W. BUDZIK, Jay M. MATTHEWS, John Jeffrey McATEE, Jacyln R. PATTERSON, Joseph E. PERO, Robert SANCHEZ, Matthew Robert SENDER, Lamont Roscoe TERRELL, David J. BEHM, James V. THOMAS
  • Patent number: 10351530
    Abstract: The present invention relates to arylcyclohexyl pyrazole compounds of Formula (I) methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: July 16, 2019
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, Astex Therapeutics Limited
    Inventors: James Callahan, Jeffrey K. Kerns, Tindy Li, Brent W. McCleland, Hong Nie, Joseph E. Pero, Thomas Glanmor Davies, Charlotte Mary Griffiths-Jones, Thomas Daniel Heightman, Steven Howard, David Norton, Marinus Leendert Verdonk, Alison Jo-Anne Woolford
  • Publication number: 20190092738
    Abstract: Disclosed are compounds of Formula A-1, or a salt thereof: Formula A-1, where J, K, Q and R1 are as defined herein, which compounds have properties for inhibiting sodium ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A-1 or their salts, and methods of treating pain (e.g. chronic pain), or cough or itch disorders using the same.
    Type: Application
    Filed: March 17, 2017
    Publication date: March 28, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Anthony J. Roecker, Mark E. Layton, Thomas J. Greshock, Joseph E. Pero, Michael J. Kelly, III, Ting Zhang
  • Publication number: 20190023715
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Application
    Filed: September 27, 2018
    Publication date: January 24, 2019
    Inventors: Zehong WAN, Xiaomin ZHANG, Jian WANG, Matthew Robert SENDER, Eric Steven MANAS, Raphael Anthony RIVERO, Joseph E PERO, Christopher Ernst NEIPP, Vipulkumar Kantibhai PATEL
  • Patent number: 10125141
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: November 13, 2018
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
  • Publication number: 20180282283
    Abstract: The present invention relates to arylcyclohexyl pyrazole compounds of Formula (I) methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Application
    Filed: October 6, 2016
    Publication date: October 4, 2018
    Inventors: James CALLAHAN, Jeffrey K. KERNS, Tindy LI, Brent W. McCLELAND, Hong NIE, Joseph E. PERO, Thomas Glanmor DAVIES, Charlotte Mary GRIFFITHS-JONES, Thomas Daniel HEIGHTMAN, Steven HOWARD, David NORTON, Marinus Leendert VERDONK, Alison Jo-Anne WOOLFORD
  • Publication number: 20180282349
    Abstract: The present invention relates to biaryl pyrazole compounds of Formula (I) methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Application
    Filed: October 6, 2016
    Publication date: October 4, 2018
    Inventors: James CALLAHAN, Jeffrey K. KERNS, Peng LI, Tindy LI, Brent W. McCLELAND, Hong NIE, Joseph E. PERO, Thomas Glanmor DAVIES, Maria GRAZIA CARR, Charlotte Mary GRIFFITHS-JONES, Thomas Daniel HEIGHTMAN, David NORTON, Marinus Leedert VERDONK, Alison Jo-Anne WOOLFORD, Hendrika Maria Gerarda WILLEMS
  • Publication number: 20170204109
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Application
    Filed: July 21, 2015
    Publication date: July 20, 2017
    Inventors: Zehong WAN, Xiaomin ZHANG, Jian WANG, Matthew Robert SWNDER, Eric Steven MANAS, Raphael Annthony RIVERO, Joseph e PERO, Christopher ERNST NEIPP, Vipuljumar Kantibhai PATEL
  • Patent number: 9624208
    Abstract: Disclosed are compounds of Formula A: Formula A, or a salt thereof, wherein “Het”, Ra, and Rb are defined herein, which have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating neuropathic pain disorders using the same.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: April 18, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joseph E. Pero, Hannah D. G. F. Lehman, Michael J. Kelly, III, Lianyun Zhao, Michael A. Rossi, Dansu Li, Kevin F. Gilbert, Scott Wolkenberg, James Mulhearn, Mark E. Layton, Pablo de Leon
  • Patent number: 9388179
    Abstract: Disclosed are compounds of Formula AA and Formula AB: wherein “Heteroaryl-1”, RA1, RA2, RB1, and RC are defined herein, which novel compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formulae AA and AB or their salts, and methods of treating neuropathic pain disorders using the same.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: July 12, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joseph E. Pero, Hannah D. G. F. Lehman, Mark E. Layton, Michael A. Rossi, Michael J. Kelly, III
  • Patent number: 9315518
    Abstract: The present invention is directed to imidazopyridin-2-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: April 19, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Hannah D. Fiji, Michael J. Kelly, III, Jeffrey C. Kern, Mark E. Layton, Joseph E. Pero, Alexander J. Reif, Michael A. Rossi